SCHEMBL1787934

SCHEMBL1787934

CO/N=C/c1ccc2c(c1)CCN(C(=O)C(F)(F)F)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.53
ESR2 Q92731 4/20 0.53
ABHD6 Q9BV23 4/20 0.41
SRC P12931 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 6/20 0.39
LMNA P02545 4/20 0.39
HTT P42858 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 3/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.38
PKM P14618 1/20 0.36
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1787935 1.00 ESR1 (0.53) ESR1ESR2ABHD6SRCHDAC6
SCHEMBL4765641 0.85 ESR1 (0.52) ESR1ESR2ABHD6HDAC6KMT2A
SCHEMBL4765646 0.85 ESR1 (0.52) ESR1ESR2ABHD6HDAC6KMT2A
SCHEMBL1790256 0.80 ESR1 (0.56) ESR1ESR2ABHD6HDAC6MEN1
SCHEMBL6857272 0.80 ESR1 (0.56) ESR1ESR2ABHD6HDAC6MEN1
SCHEMBL2309023 0.77 ESR1 (0.85) ESR1ESR2ABHD6HDAC6
SCHEMBL373697 0.73 ESR2 (0.83) ESR1ESR2ABHD6HDAC6
SCHEMBL31173299 0.73 ESR2 (0.68) ESR1ESR2ABHD6HDAC6MEN1
SCHEMBL2334651 0.73 ESR2 (0.68) ESR1ESR2ABHD6HDAC6MEN1
SCHEMBL1787035 0.72 ESR1 (0.56) ESR1ESR2ABHD6HDAC6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011083316-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 WO disclosed
US-20110172204-A1 COMPOUNDS AND THEIR USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 US disclosed
WO-2011083314-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 WO disclosed
WO-2011083315-A1 COMPOUNDS AND THEIR USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 WO disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 ESR1 2324/4885ESR2 1902/4885ABHD6 1634/4885
US-20110172204-A1 COMPOUNDS AND THEIR USE HRH3, HRH4, HRH2 ESR1 573/4885ESR2 427/4885ABHD6 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.